מדינה: אירלנד
שפה: אנגלית
מקור: HPRA (Health Products Regulatory Authority)
LEUPRORELIN ACETATE
Takeda UK Limited
L02AE02
LEUPRORELIN ACETATE
11.25 Milligram
Pdr+Solv for Susp for Inj
Product subject to prescription which may not be renewed (A)
Gonadotropin releasing hormone analogues
Transfer Pending
2011-04-08
Prostap 3 DCS IE 1 PACKAGE LEAFLET: INFORMATION FOR THE USER PROSTAP ® 3 DCS 11.25 mg Powder and Solvent for Prolonged-release Suspension for Injection in Pre-filled Syringe Leuprorelin acetate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What PROSTAP 3 is and what it is used for 2. What you need to know before you take PROSTAP 3 3. How to take PROSTAP 3 4. Possible side effects 5. How to store PROSTAP 3 6. Contents of the pack and other information 1. WHAT PROSTAP 3 IS AND WHAT IT IS USED FOR PROSTAP 3 is a synthetic hormone which can be used to reduce the levels of testosterone and estrogen circulating in the body. PROSTAP 3 is used to treat prostate cancer in men and endometriosis and uterine fibroids in women. USE IN CHILDREN: Leuprorelin 3 Month Depot is a synthetic hormone which can be used to reduce the levels of testosterone and estrogen circulating in the body. Leuprorelin 3 Month Depot is used to treat premature puberty which is caused by a release of certain hormones from the pituitary gland (central precocious puberty) in girls under 9 years of age and boys under 10 years of age. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PROSTAP 3 USE IN CHILDREN: קרא את המסמך השלם
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT PROSTAP 3 DCS 11.25 mg Powder and Solvent for Prolonged-release Suspension for Injection in Pre-filled Syringe 2 QUALITATIVE AND QUANTITATIVE COMPOSITION POWDER: contains 11.25 mg leuprorelin acetate. SOLVENT: Solvent contains approximately 0.4mg (<1mmol) sodium (as carmellose sodium). When reconstituted with sterile solvent, the suspension contains 11.25mg of leuprorelin acetate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder and solvent for prolonged-release suspension for injection in pre-filled syringe (Dual Chamber Syringe). Powder: A sterile, lyophilised, white, odourless powder. Solvent: A clear odourless, slightly viscous, sterile solvent. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS (i) Management of prostatic carcinoma for which a suppression of testosterone is indicated. (ii) Management of estrogen dependent gynaecological disorders including the management of pain and lesions associated with endometriosis. (iii) Preoperative management of uterine fibroids to reduce their size and associated bleeding. In children: Treatment of central precocious puberty (girls under 9 years of age, boys under 10 years of age). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Male Adults: The usual recommended dose is 11.25mg presented as a 3 month depot injection and administered as a single subcutaneous or intramuscular injection at intervals of 3 months. The majority of patients will respond to this dosage. PROSTAP 3 therapy should not be discontinued when remission or improvement occurs. Response to PROSTAP 3 therapy may be monitored by clinical parameters and by measuring serum levels of testosterone and acid phosphatase. Clinical studies have shown that testosterone levels increased du קרא את המסמך השלם